MA54009A1 - Formulation d'afabicine et son procédé de préparation - Google Patents
Formulation d'afabicine et son procédé de préparationInfo
- Publication number
- MA54009A1 MA54009A1 MA54009A MA54009A MA54009A1 MA 54009 A1 MA54009 A1 MA 54009A1 MA 54009 A MA54009 A MA 54009A MA 54009 A MA54009 A MA 54009A MA 54009 A1 MA54009 A1 MA 54009A1
- Authority
- MA
- Morocco
- Prior art keywords
- afabicin
- formulation
- preparation
- compositions
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques solides contenant de l'afabicine présentant des caractéristiques supérieures de dissolution. Cet effet bénéfique est accompli par la présence d'un composé histidine pour la fabrication des compositions. La présente invention concerne en outre des procédés de préparation de telles compositions et des utilisations associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157255 | 2019-02-14 | ||
PCT/EP2020/053882 WO2020165407A1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA54009A1 true MA54009A1 (fr) | 2022-05-31 |
MA54009B1 MA54009B1 (fr) | 2022-10-31 |
Family
ID=65440901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA54009A MA54009B1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Country Status (27)
Country | Link |
---|---|
US (1) | US20220142993A1 (fr) |
EP (1) | EP3923914B1 (fr) |
JP (1) | JP7383715B2 (fr) |
KR (1) | KR20210127187A (fr) |
CN (2) | CN113423390B (fr) |
AU (1) | AU2020223515A1 (fr) |
BR (1) | BR112021015825B1 (fr) |
CA (1) | CA3129508A1 (fr) |
CL (1) | CL2021002149A1 (fr) |
CY (1) | CY1126077T1 (fr) |
DK (1) | DK3923914T3 (fr) |
EA (1) | EA202192246A1 (fr) |
ES (1) | ES2944535T3 (fr) |
FI (1) | FI3923914T3 (fr) |
HR (1) | HRP20230437T1 (fr) |
HU (1) | HUE062061T2 (fr) |
IL (1) | IL285204A (fr) |
LT (1) | LT3923914T (fr) |
MA (1) | MA54009B1 (fr) |
MX (1) | MX2021009799A (fr) |
PL (1) | PL3923914T3 (fr) |
PT (1) | PT3923914T (fr) |
RS (1) | RS64158B1 (fr) |
SG (1) | SG11202108591PA (fr) |
SI (1) | SI3923914T1 (fr) |
TN (1) | TN2021000159A1 (fr) |
WO (1) | WO2020165407A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202106061VA (en) | 2018-12-21 | 2021-07-29 | Acurx Pharmaceuticals Llc | Dna polymerase iiic inhibitors and use thereof |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60230934D1 (de) * | 2001-04-06 | 2009-03-05 | Affinium Pharm Inc | Fab-i-inhibitoren |
CN101415701A (zh) * | 2005-12-05 | 2009-04-22 | Affinium医药公司 | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 |
EP2861608B8 (fr) | 2012-06-19 | 2019-06-19 | Debiopharm International SA | Dérivés de type promédicament du (e)-n-méthyl-n-((3-méthylbenzofuran-2-yl) méthyl)-3-(7-oxo-5,6,7,8-tétrahydro-l,8-naphtyridin-3-yl)acrylamide |
JP6998881B2 (ja) | 2016-02-26 | 2022-02-10 | デビオファーム・インターナショナル・エス・アー | 糖尿病性足感染症の処置のための医薬 |
-
2020
- 2020-02-14 BR BR112021015825-1A patent/BR112021015825B1/pt active IP Right Grant
- 2020-02-14 AU AU2020223515A patent/AU2020223515A1/en active Pending
- 2020-02-14 KR KR1020217028702A patent/KR20210127187A/ko unknown
- 2020-02-14 MX MX2021009799A patent/MX2021009799A/es unknown
- 2020-02-14 SG SG11202108591PA patent/SG11202108591PA/en unknown
- 2020-02-14 PL PL20704307.6T patent/PL3923914T3/pl unknown
- 2020-02-14 DK DK20704307.6T patent/DK3923914T3/da active
- 2020-02-14 EA EA202192246A patent/EA202192246A1/ru unknown
- 2020-02-14 JP JP2021545458A patent/JP7383715B2/ja active Active
- 2020-02-14 ES ES20704307T patent/ES2944535T3/es active Active
- 2020-02-14 MA MA54009A patent/MA54009B1/fr unknown
- 2020-02-14 TN TNP/2021/000159A patent/TN2021000159A1/en unknown
- 2020-02-14 CN CN202080014005.3A patent/CN113423390B/zh active Active
- 2020-02-14 WO PCT/EP2020/053882 patent/WO2020165407A1/fr active Application Filing
- 2020-02-14 LT LTEPPCT/EP2020/053882T patent/LT3923914T/lt unknown
- 2020-02-14 CN CN202310544746.8A patent/CN116327781A/zh active Pending
- 2020-02-14 SI SI202030183T patent/SI3923914T1/sl unknown
- 2020-02-14 EP EP20704307.6A patent/EP3923914B1/fr active Active
- 2020-02-14 CA CA3129508A patent/CA3129508A1/fr active Pending
- 2020-02-14 US US17/430,616 patent/US20220142993A1/en active Pending
- 2020-02-14 FI FIEP20704307.6T patent/FI3923914T3/fi active
- 2020-02-14 RS RS20230315A patent/RS64158B1/sr unknown
- 2020-02-14 HU HUE20704307A patent/HUE062061T2/hu unknown
- 2020-02-14 PT PT207043076T patent/PT3923914T/pt unknown
- 2020-02-14 HR HRP20230437TT patent/HRP20230437T1/hr unknown
-
2021
- 2021-07-28 IL IL285204A patent/IL285204A/en unknown
- 2021-08-13 CL CL2021002149A patent/CL2021002149A1/es unknown
-
2023
- 2023-05-09 CY CY20231100220T patent/CY1126077T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021002149A1 (es) | 2022-03-04 |
US20220142993A1 (en) | 2022-05-12 |
EP3923914A1 (fr) | 2021-12-22 |
CN113423390A (zh) | 2021-09-21 |
FI3923914T3 (fi) | 2023-04-27 |
BR112021015825B1 (pt) | 2024-03-12 |
JP2022520170A (ja) | 2022-03-29 |
RS64158B1 (sr) | 2023-05-31 |
IL285204A (en) | 2021-09-30 |
CA3129508A1 (fr) | 2020-08-20 |
JP7383715B2 (ja) | 2023-11-20 |
AU2020223515A1 (en) | 2021-08-19 |
EP3923914B1 (fr) | 2023-04-12 |
MX2021009799A (es) | 2021-09-08 |
CN116327781A (zh) | 2023-06-27 |
PT3923914T (pt) | 2023-05-04 |
CY1126077T1 (el) | 2023-11-15 |
HRP20230437T1 (hr) | 2023-07-07 |
BR112021015825A2 (pt) | 2021-10-13 |
MA54009B1 (fr) | 2022-10-31 |
SI3923914T1 (sl) | 2023-08-31 |
PL3923914T3 (pl) | 2023-08-07 |
KR20210127187A (ko) | 2021-10-21 |
LT3923914T (lt) | 2023-07-25 |
TN2021000159A1 (en) | 2023-04-04 |
CN113423390B (zh) | 2023-05-23 |
ES2944535T3 (es) | 2023-06-22 |
EA202192246A1 (ru) | 2021-11-18 |
HUE062061T2 (hu) | 2023-09-28 |
WO2020165407A1 (fr) | 2020-08-20 |
SG11202108591PA (en) | 2021-09-29 |
DK3923914T3 (da) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54009A1 (fr) | Formulation d'afabicine et son procédé de préparation | |
MA30762B1 (fr) | Anticorps specifiques du prlr et leurs utilisations | |
MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
FR2421929A1 (fr) | Compositions, bains de placage et procede pour l'electrodeposition d'etain et/ou de plomb | |
MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation | |
MA44205A (fr) | Comprimé orodispersible comprenant estetrol | |
WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
FR3086943B1 (fr) | Copolymere d'ethylene et de beta-farnesene | |
MA53189B2 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
FR3100723B1 (fr) | Procédé de préparation d’atomes métalliques isolés ou d’un mélange d’atomes métalliques isolés et de nanoparticules métalliques sur matériau carboné | |
CA2473203A1 (fr) | Composition pharmaceutique orodispersible d'ivabradine | |
FR2401132A1 (fr) | Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant | |
FR3105976B1 (fr) | Composition de matière et procédé de préparation de celle-ci | |
MA34054B1 (fr) | Bromhydrate d'agomelatine hydrate et sa preparation | |
FR3105787B1 (fr) | Procede de preparation de particules d’oxyde de zinc enrobees par pyrolyse par projection de flamme | |
KR950003282A (ko) | 살균성 스피로헤테로시클릭 화합물 및 이들의 제조방법 | |
MA53043A1 (fr) | Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation | |
US2614918A (en) | Method of setting fruit and composition therefor | |
FR2403798A1 (fr) | Compositions synergiques a base de disulfure de bis(2-pyridyl-1-oxyde et leur utilisation pour leur activite anti-inflammatoire | |
FR2789589A1 (fr) | Procede de conditionnement de compositions pharmaceutiques et compositions de ticlopidine obtenues par ce procede. | |
FR3100134B1 (fr) | PRINCIPE ACTIF COSMETIQUE OBTENU PAR BIOCONVERSION PARLactobacillus arizonensisDE SON SUBSTRAT ORIGINEL, PROCEDE D’OBTENTION, COMPOSITION L’INCLUANT ET UTILISATIONS. | |
FR2594118A1 (fr) | Adjuvant pour mortiers et betons |